Biomarker · Gene alteration
EGFR T790M
EGFR exon 20 point mutation p.T790M detected in tumor tissue or plasma; an acquired resistance mutation to earlier-generation EGFR inhibitors used as a predictive marker for third-generation agents.
CI-BIO-00000011EGFRgraph →NCIt C98503
Also calledp.T790M · gatekeeper mutation · c.2369C>T
Derived
Associated cancers (5)
Cancers mapped in ACCEPTED CIViC predictive, prognostic or diagnostic items whose variant (molecular markers) or gene (gene-level markers) is in this biomarker's scope. Counts by type and native level; each row links to the cancer's evidence tab.
| Cancer | Items | Predictive | Prognostic | Diagnostic | Levels A / B / C / D / E |
|---|---|---|---|---|---|
| Lung Non-Small Cell Carcinoma | 27 | 25 | 2 | — | 5 / 10 / 2 / 9 / 1 |
| Lung Adenocarcinoma | 6 | 6 | — | — | 0 / 1 / 5 / 0 / 0 |
| Malignant Lung Neoplasm | 1 | 1 | — | — | 0 / 0 / 0 / 1 / 0 |
| Malignant Neoplasm | 1 | 1 | — | — | 0 / 0 / 0 / 1 / 0 |
| Pancreatic Adenocarcinoma |
Derived
Drugs with predictive evidence (13)
Therapies named in in-scope PREDICTIVE CIViC items, plus targets of PREDICTS_RESPONSE_TO knowledge edges from in-scope variants. Sensitivity and resistance are counted separately and never merged into a verdict.
| Drug | CIViC items | Sensitivity | Resistance | Best level | Edges (S / R) | Cancer context |
|---|---|---|---|---|---|---|
| OsimertinibSmall Molecule | 13 | 12 | 1 | A | 11 / 1 | Lung Adenocarcinoma, Lung Non-Small Cell Carcinoma, Pancreatic Adenocarcinoma |
| GefitinibSmall Molecule | 7 | — | 7 | B | 0 / 7 |
Curated evidence
Predictive evidence items (34)
ACCEPTED CIViC predictive items in scope, grouped by molecular profile and therapy with native level, direction and cancer context. 50 per page.
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 23470965
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| EGFR T790M28 | ||||||||
| Erlotinib + | ||||||||
Regulatory
Approvals mentioning the linked drugs (190)
Approval records of the derived drug set, plus records whose indication text names this biomarker. Each record names its authority, jurisdiction, indication text and status — a drug approved in one jurisdiction for one indication is not 'approved' in general, and an approval listed here is not necessarily restricted to this biomarker.
- Source
- Health Canada — Drug Product Database (DPD)
- Dataset
- Health Canada DPD
- Version
- dpd-2026-09-11
- Retrieved
- Sep 11, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- regulatory
- License
- Open Government Licence – Canada (https://open.canada.ca/en/open-government-licence-canada)
- Run
- ING-HEALTHCANADADPD-20260911-000001
Clinical trials
Active trials (271)
Trials with an active ClinicalTrials.gov status, an intervention mapped to a derived drug and a condition mapped to an associated cancer. 124 recruiting · 91 active phase 3 · 1,127 in any status. Most recently updated first, 50 per page.
- Source
- ClinicalTrials.gov
- Dataset
- ClinicalTrials.gov API v2 studies
- Retrieved
- Sep 30, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03793179 | Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer | active not recruiting | Phase 3 |
Literature
Linked publications (32)
Publications linked to the scope variant(s) through PubMed entity edges; 25 per page, newest first.
- Source
- PubMed (NLM)
- Dataset
- PubMed E-utilities
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)